JP2022514381A5 - - Google Patents
Info
- Publication number
- JP2022514381A5 JP2022514381A5 JP2021535670A JP2021535670A JP2022514381A5 JP 2022514381 A5 JP2022514381 A5 JP 2022514381A5 JP 2021535670 A JP2021535670 A JP 2021535670A JP 2021535670 A JP2021535670 A JP 2021535670A JP 2022514381 A5 JP2022514381 A5 JP 2022514381A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783136P | 2018-12-20 | 2018-12-20 | |
| US62/783,136 | 2018-12-20 | ||
| US201962855993P | 2019-06-01 | 2019-06-01 | |
| US62/855,993 | 2019-06-01 | ||
| PCT/US2019/068103 WO2020132600A1 (en) | 2018-12-20 | 2019-12-20 | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514381A JP2022514381A (ja) | 2022-02-10 |
| JPWO2020132600A5 JPWO2020132600A5 (https=) | 2022-12-19 |
| JP2022514381A5 true JP2022514381A5 (https=) | 2022-12-19 |
Family
ID=71101983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535670A Pending JP2022514381A (ja) | 2018-12-20 | 2019-12-20 | 臓器移植の慢性抗体介在性拒絶反応の処置でのクラザキズマブ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220073605A1 (https=) |
| EP (1) | EP3897718A4 (https=) |
| JP (1) | JP2022514381A (https=) |
| KR (1) | KR20210106521A (https=) |
| CN (1) | CN113194996B (https=) |
| AU (1) | AU2019404553A1 (https=) |
| BR (1) | BR112021010615A2 (https=) |
| CA (1) | CA3121934A1 (https=) |
| WO (1) | WO2020132600A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20220288202A1 (en) * | 2019-09-04 | 2022-09-15 | Cedars-Sinai Medical Center | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients |
| WO2025122579A1 (en) * | 2023-12-04 | 2025-06-12 | Cedars-Sinai Medical Center | Cadherin 6 expression status in determination of renal fibrosis and related uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| HUE032563T2 (en) * | 2007-05-21 | 2017-09-28 | Alderbio Holdings Llc | Antibodies to IL-6 and their use |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| EP2834368A2 (en) * | 2012-04-04 | 2015-02-11 | Assistance Publique - Hopitaux De Paris | Endothelial cells activation biomarkers characterizing antibody mediated rejection and uses thereof |
| JP6636803B2 (ja) * | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| NZ719724A (en) * | 2013-11-22 | 2022-08-26 | Takeda Pharmaceuticals Co | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| US11065319B2 (en) * | 2014-02-04 | 2021-07-20 | 3Dt Holdings, Llc | Methods for diagnosing and reducing incidences of cardiac allograft rejection |
| US20170022280A1 (en) * | 2015-07-24 | 2017-01-26 | Cedars-Sinai Medical Center | Method for treating antibody-mediated rejection post-transplantation |
| CN111867627A (zh) * | 2018-01-04 | 2020-10-30 | 维塔里斯股份有限公司 | 抗IL-6抗体例如克拉扎珠单抗(Clazakizumab)用于使实体器官移植接受者脱敏和/或用于预防、稳定或减轻抗体介导的排斥(ABMR)的用途 |
| JP2022512937A (ja) * | 2018-11-08 | 2022-02-07 | セダーズ－シナイ メディカル センター | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
-
2019
- 2019-12-20 US US17/415,993 patent/US20220073605A1/en not_active Abandoned
- 2019-12-20 KR KR1020217022866A patent/KR20210106521A/ko active Pending
- 2019-12-20 JP JP2021535670A patent/JP2022514381A/ja active Pending
- 2019-12-20 CN CN201980084166.7A patent/CN113194996B/zh active Active
- 2019-12-20 EP EP19900083.7A patent/EP3897718A4/en active Pending
- 2019-12-20 AU AU2019404553A patent/AU2019404553A1/en active Pending
- 2019-12-20 CA CA3121934A patent/CA3121934A1/en active Pending
- 2019-12-20 BR BR112021010615A patent/BR112021010615A2/pt unknown
- 2019-12-20 WO PCT/US2019/068103 patent/WO2020132600A1/en not_active Ceased
-
2025
- 2025-03-17 US US19/081,867 patent/US20250263480A1/en active Pending